Retatrutide functions as a triple receptor agonist, targeting GLP-1, GIP, and glucagon pathways, whereas Mounjaro contains tirzepatide, a dual agonist that activates only GLP-1 and GIP receptors. Clinical Phase 2 studies indicate that retatrutide delivers an average weight reduction of 22.5%, slightly outperforming tirzepatide at approximately 22%, primarily due to its added glucagon activity, which helps increase overall energy expenditure and enhances fat burning.
peptides for weight loss
Research-grade retatrutide peptide branch supplier in USA. Independently verified at 99.38% purity by Janoshik Analytical.






